Nephrodi Therapeutics Lands Financing To Develop A Treatment For Nephrogenic Diabetes Insipidus, An Orphan Disease
Nephrodi Therapeutics Lands Financing To Develop A Treatment For Nephrogenic Diabetes Insipidus, An Orphan Disease
05/12/21, 11:15 AM
Location
NephroDI Therapeutics, Inc., a biopharmaceutical company developing NDI-5033 for the X-linked/congenital form of Nephrogenic Diabetes Insipidus (NDI), today announced a seed investment from Xontogeny, LLC to advance their lead program through critical preclinical work.
Company Info
Location
philadelphia, pennsylvania, united states
Additional Info
NephroDI Therapeutics is a pharmaceutical company that focuses on concentration disorders of the kidney. The initial clinical indication for its orally administered lead small molecule is for Nephrogenic Diabetes Insipidus (NDI) in children, a pediatric orphan indication. For more information, please visit: www.nephrodi.com.